Integrated healthcare group
From active ingredient to the point of care.
Pranda Health operates across active pharmaceutical ingredients, finished dosage manufacturing, global supply chain and clinical services in the United States — so that medicine availability can be measured rather than assumed.
ScrollWhat we do
Four parts of one chain.
Most pharmaceutical supply is assembled from separate parties, each responsible for one link. We hold more of the chain ourselves, which is what allows accountability for availability to sit in one place.
Active pharmaceutical ingredients
API and intermediate manufacture, custom synthesis, process development and optimisation, scale-up and technology transfer.
Active ingredientsFinished dosage manufacturing
Oral solid dosage manufacture with a specialism in modified-release pellet technology, from formulation development through to validated commercial batches.
Finished dosageGlobal supply chain
Supplier qualification, material traceability, demand planning, safety-stock policy, serialisation and continuity planning.
Supply chainClinical services, United States
The group also operates healthcare facilities in the United States — which is why we treat a stockout as a clinical problem and not only a logistics one.
The problem worth solving
A medicine that exists somewhere is not a medicine on the shelf.
In most import-dependent health systems a product passes through manufacturers, international traders, agents, importers, distributors, warehouses, public procurement, hospitals and pharmacies before it reaches a patient.
Some of those functions are legally and operationally essential. Others are simply accumulated distance. Every avoidable handoff weakens demand visibility, lengthens replenishment cycles, adds mark-up, and blurs the question that actually matters: who is answerable when the shelf is empty?
We work the other way around. The manufacturer stays connected to local inventory, service levels and product performance — through properly authorised local channels, never around them.
International reach
Built one authorisation at a time.
Market access in pharmaceuticals is not a map exercise. Trade agreements create routes to investigate, not automatic entry. We expand in concentric horizons and enter each one only when the last is genuinely operating.
Quality
Built for regulated markets, described precisely.
Our facilities are designed and operated in accordance with current Good Manufacturing Practice principles and/or other applicable requirements, under quality systems built to support products intended for regulated markets.
Documented quality systems
Change control, deviation management, supplier qualification, in-process control, stability testing and batch release are governed by a documented quality management system across every stage of production.
On-site analytical capability
Manufacturing is supported by analytical laboratories, with methods validated against recognised pharmacopoeial standards and full batch documentation available to customers.
Audit-ready by design
We support customer audits, technical due diligence and regulatory documentation requests, and maintain the validation records and technical files customers need for their own filings.
The group at a glance
Where we are, and for how long.
Figures reflect management-supplied information as at August 2026.
Next step
Let’s talk about supply in your market.
We work with health ministries, procurement agencies, hospital groups, distributors and manufacturing partners.